换一批
换一批Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions.
作者：
关键词
Ebola vaccineV920 vaccine Ervebo?effectiveness of rVSV-ΔG-ZEBOV-GPimmunogenicity of rVSV-ΔG-ZEBOV-GPrVSV-ΔG-ZEBOV-GP in high-income countriesrVSV-ΔG-ZEBOV-GP vaccinerVSV-ΔG-ZEBOV-GP vaccine in low-and-middle-income countriesring vaccinationrisk–benefit analysis of rVSV-ΔG-ZEBOV-GPsafety of rVSV-ΔG-ZEBOV-GP
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);儿童(Child);临床试验(主题)(Clinical Trials as Topic);埃博拉疫苗(Ebola Vaccines);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);男(雄)性(Male);中年人(Middle Aged);妊娠(Pregnancy);危险性评估(Risk Assessment);治疗结果(Treatment Outcome);接种(Vaccination);青年人(Young Adult)
DOI
10.2217/fmb-2019-0237
PMID
32030996
发布时间
2021-04-05
- 浏览0
Future microbiology
85-106页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
